Want to see IRWD full AI Analyst Report?
Top Page
Ironwood Pharma
(NASDAQ:IRWD)
Select Model
Select Model
Rating:67Neutral
Price Target:
$4.50
▲(21.29% Upside)
Action:Reiterated
Date:08/07/26
IRWD scores above average mainly due to improving TTM operating results and strong cash flow, reinforced by positive earnings-call guidance and continued deleveraging plans. The score is held back by meaningful balance-sheet risk (negative equity) and reliance on a single core product, while technicals and a low P/E provide additional support.
Positive Factors
Strong cash generation
Recent TTM operating and free cash flow strength provides durable internal funding for commercialization, R&D and debt paydown. High cash conversion versus earnings reduces reliance on financing, supporting runway for programs and strategic flexibility over the next several quarters.
Negative Factors
High product concentration
Reliance on a single product concentrates commercial risk from payers, pricing, competition and utilization. Any adverse formulary actions, generics, or demand shifts could meaningfully reduce cash flow and impair the firm's ability to fund development or meet leverage targets over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Recent TTM operating and free cash flow strength provides durable internal funding for commercialization, R&D and debt paydown. High cash conversion versus earnings reduces reliance on financing, supporting runway for programs and strategic flexibility over the next several quarters.
Read all positive factors
Ironwood Pharma (IRWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$712.18M
Dividend YieldN/A
Average Volume (3M)2.34M
Price to Earnings (P/E)5.4
Beta (1Y)1.01
Revenue Growth26.19%
EPS GrowthN/A
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.80
Shares Outstanding165,239,940
10 Day Avg. Volume1,576,550
30 Day Avg. Volume2,343,106
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.09
Price to Sales (P/S)1.85
P/FCF Ratio4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.19
Revenue Forecast (FY)$460.02M
Ironwood Pharma Business Overview & Revenue Model
Company Description
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a gu...
How the Company Makes Money
Ironwood primarily makes money from its role in the commercialization of LINZESS (linaclotide) in the United States. Its revenue is largely driven by (1) collaboration-based income tied to LINZESS sales, including a share of profits or other contr...
Ironwood Pharma Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed a predominantly positive commercial and financial story driven by LINZESS: strong Q2 sales, significant YTD growth, an upward revision to full-year guidance, a pediatric label expansion, and robust quarterly profitability. Clinical progress on apraglutide (initiation of STARS-2 and supportive STARS/STARS-Extend data) and actions to strengthen the balance sheet (repayment of convertible notes and target to reduce gross leverage) are additional positives. Offsetting risks include dependence on LINZESS for revenue, early-stage enrollment uncertainty for STARS-2, remediation required after a prior dosing kit error, anticipated higher R&D/SG&A spend in H2, and a modest cash balance that increases reliance on operating cash flow and receivables.Positive Updates
Strong LINZESS Commercial Performance
Q2 U.S. net sales for LINZESS were $282.3M (14% year-over-year). Year-to-date (first half) LINZESS U.S. net sales reached $555M, up 44% YoY. Q2 EUTRx volume growth was +4% YoY and +5% year-to-date, with management expecting mid-single-digit demand growth for the full year.
Negative Updates
Concentration Risk on LINZESS
Company remains heavily dependent on LINZESS as the primary revenue driver (relying on continued price and demand improvements) which concentrates commercial risk in a single product despite strong current performance.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong LINZESS Commercial Performance
Q2 U.S. net sales for LINZESS were $282.3M (14% year-over-year). Year-to-date (first half) LINZESS U.S. net sales reached $555M, up 44% YoY. Q2 EUTRx volume growth was +4% YoY and +5% year-to-date, with management expecting mid-single-digit demand growth for the full year.
Read all positive updates
Company Guidance
Ironwood raised full‑year 2026 guidance driven by LINZESS strength, now expecting LINZESS U.S. net sales of $1.15–$1.20 billion (greater than 30% year‑over‑year growth) supported by mid‑single‑digit prescription demand growth and improved net price; company revenue guidance is $460–$485 million and adjusted EBITDA is expected to be greater than $310 million. In Q2 LINZESS U.S. net sales were $282.3 million (H1 net sales $555 million, +44% YTD), EUTRx volume growth was +4% in Q2 and +5% YTD, and management expects sequential quarterly net sales to build with Q4 as the strongest quarter. Q2 company results included total revenue of $113 million, GAAP net income of $51.3 million and adjusted EBITDA of $83 million; the company ended the quarter with $79 million cash, $113 million collaboration receivables, repaid $200 million of convertible notes, and expects to finish 2026 with gross debt under $300 million and gross leverage below 1x while using LINZESS cash flow to further reduce debt.Ironwood Pharma Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
38
Negative
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 389.32M | 296.15M | 351.41M | 442.74M | 410.60M | 413.75M |
| Gross Profit | 388.40M | 296.15M | 343.86M | 436.59M | 409.18M | 343.35M |
| EBITDA | 241.42M | 104.65M | 97.73M | 197.41M | 261.44M | 233.74M |
| Net Income | 129.87M | 24.02M | 880.00K | -1.00B | 175.06M | 528.45M |
Balance Sheet | ||||||
| Total Assets | 285.13M | 396.90M | 350.91M | 471.07M | 1.10B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 79.13M | 215.46M | 88.56M | 92.15M | 656.20M | 620.13M |
| Total Debt | 396.87M | 597.80M | 599.48M | 715.54M | 415.92M | 475.80M |
| Total Liabilities | 446.97M | 658.74M | 652.24M | 817.37M | 448.14M | 521.02M |
| Stockholders Equity | -161.84M | -261.83M | -301.33M | -346.30M | 652.38M | 605.91M |
Cash Flow | ||||||
| Free Cash Flow | 185.55M | 127.01M | 103.41M | 183.15M | 273.63M | 261.63M |
| Operating Cash Flow | 185.56M | 127.04M | 103.55M | 183.43M | 273.76M | 261.89M |
| Investing Cash Flow | -1.00K | -34.00K | -142.00K | -1.03B | -136.00K | -265.00K |
| Financing Cash Flow | -199.57M | 216.00K | -106.97M | 277.16M | -237.55M | -4.55M |
Ironwood Pharma Technical Analysis
Positive
3.71
Price Trends
3.97
Positive
3.90
Positive
3.79
Positive
Market Momentum
0.07
Negative
55.07
Neutral
48.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Positive. The current price of 3.71 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 3.97, and below the 200-day MA of 3.79, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 48.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRWD.
Ironwood Pharma Risk Analysis
Ironwood Pharma disclosed 46 risk factors in its most recent earnings report. Ironwood Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ironwood Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.76B | 15.85 | 19.19% | ― | 30.90% | ― | |
69 Neutral | $916.82M | 65.32 | 2.13% | ― | 5.71% | ― | |
67 Neutral | $712.18M | 5.41 | -57.40% | ― | 26.19% | ― | |
62 Neutral | $919.04M | 18.45 | 15.96% | ― | 14.31% | 34.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $709.18M | -3.17 | -24.55% | ― | -0.86% | -35.64% |
* Healthcare Sector Average
IRWD
Ironwood Pharma
4.31
3.18
281.42%
PCRX
Pacira Pharmaceuticals
23.00
-1.89
-7.59%
ANIP
ANI Pharmaceuticals
76.54
-13.17
-14.68%
EVO
Evotec AG
1.96
-1.72
-46.74%
COLL
Collegium Pharmaceutical
28.23
-9.96
-26.08%
Ironwood Pharma Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Ironwood Pharma Shareholders Reaffirm Board and Governance Structure
Positive
Jun 18, 2026
At its June 16, 2026 annual meeting of stockholders, Ironwood Pharmaceuticals, Inc. saw shareholders elect eight director nominees to one-year terms, reaffirming the existing board’s oversight of the company. Investors also endorsed, on an a...
Business Operations and StrategyFinancial Disclosures
Ironwood Pharma Strengthens Balance Sheet With Note Repayment
Positive
Jun 15, 2026
On June 15, 2026, Ironwood Pharmaceuticals, Inc. fully repaid the $200 million principal on its 1.50% convertible senior notes due 2026 at scheduled maturity using available cash on hand. No noteholders chose to convert their securities into equit...
Executive/Board Changes
Ironwood Pharma Announces CFO Resignation and Interim Successor
Neutral
May 13, 2026
On May 8, 2026, Ironwood Pharmaceuticals said Senior Vice President and Chief Financial Officer Gregory Martini will resign effective May 15, 2026, with the company noting his departure is not related to any dispute over its financial reporting. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.